Literature DB >> 18187523

MAPKs and their relevance to arthritis and inflammation.

T Thalhamer1, M A McGrath, M M Harnett.   

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which imbalances in pro- and anti-inflammatory cytokines promote the induction of autoimmunity, inflammation and joint destruction. The importance of inflammatory cytokines in the pathogenesis of RA has been underscored by the success of biologics that act to block the effects of cytokines, such as tumour necrosis factor-alpha, interleukin (IL)-1 or IL-6, in treating disease. Mitogen-activated protein kinases (MAPKs) have been implicated as playing key regulatory roles in the production of these pro-inflammatory cytokines and downstream signalling events leading to joint inflammation and destruction. This article reviews the evidence that MAPKs play important roles in the pathogenesis of RA and discusses their therapeutic potential as drug targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187523     DOI: 10.1093/rheumatology/kem297

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  167 in total

Review 1.  Molecular insights into phytochemicals exhibiting anti-arthritic activity: systematic review : John Di Battista.

Authors:  P Sivasakthi; E Sanmuga Priya; P Senthamil Selvan
Journal:  Inflamm Res       Date:  2021-05-24       Impact factor: 4.575

2.  Activation of p38 mitogen-activated protein kinase by norepinephrine in T-lineage cells.

Authors:  Melissa D Lajevic; Samia Suleiman; Rhonna L Cohen; Donald A Chambers
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

3.  Structural basis for the regulation of the mitogen-activated protein (MAP) kinase p38α by the dual specificity phosphatase 16 MAP kinase binding domain in solution.

Authors:  Ganesan Senthil Kumar; Heiko Zettl; Rebecca Page; Wolfgang Peti
Journal:  J Biol Chem       Date:  2013-08-07       Impact factor: 5.157

4.  IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway.

Authors:  Rana Al-Sadi; Dongmei Ye; Hamid M Said; Thomas Y Ma
Journal:  Am J Pathol       Date:  2010-11       Impact factor: 4.307

5.  Beyond Autoantibodies: Biologic Roles of Human Autoreactive B Cells in Rheumatoid Arthritis Revealed by RNA-Sequencing.

Authors:  Ankit Mahendra; Xingyu Yang; Shaza Abnouf; Jay R T Adolacion; Daechan Park; Sanam Soomro; Jason Roszik; Cristian Coarfa; Gabrielle Romain; Keith Wanzeck; S Louis Bridges; Amita Aggarwal; Peng Qiu; Sandeep K Agarwal; Chandra Mohan; Navin Varadarajan
Journal:  Arthritis Rheumatol       Date:  2019-02-23       Impact factor: 10.995

6.  The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia.

Authors:  Hengning Ke; Rebecca Harris; Jonathan L Coloff; Jane Y Jin; Benjamin Leshin; Paula Miliani de Marval; Shiying Tao; Jeffrey C Rathmell; Russell P Hall; Jennifer Y Zhang
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

Review 7.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

8.  Activated protein C inhibits proliferation and tumor necrosis factor α-stimulated activation of p38, c-Jun NH2-terminal kinase (JNK) and Akt in rheumatoid synovial fibroblasts.

Authors:  Sohel M Julovi; Kaitlin Shen; Kelly Mckelvey; Nikita Minhas; Lyn March; Christopher J Jackson
Journal:  Mol Med       Date:  2013-10-24       Impact factor: 6.354

9.  The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Authors:  Jennifer Y Zhang; Maria Angelica Selim
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease.

Authors:  M M Harnett; A J Melendez; W Harnett
Journal:  Clin Exp Immunol       Date:  2009-12-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.